![]() |
| Jonasz Jeremiasz Weber, Rana Dilara Incebacak Eltemur, Priscila Pereira Sena, Huu Phuc Nguyen (from left) worked out the study together. Credit: © Pengfei Qi |
Similar to Alzheimer's, the hereditary disease Spinocerebellar Ataxia Type 17 (SCA17) leads to the demise of brain nerve cells and the premature death of those affected. The exact mechanisms of the disease are unknown, so there are no treatment approaches to date. Researchers of human genetics at the Ruhr University Bochum (RUB) around Dr. Jonasz Weber now suspects a class of protein-splitting enzymes, so-called calpaines, to contribute to the disease. In the model, the Calpaine was switched off to stop the course. The researchers report in the journal Cellular and Molecular Life Sciences.
Changed blueprint of a protein
Spinocerebellar ataxia type 17 (SCA17) is a rare, hereditary disease of the human brain. Due to the pathological change in a gene that contains the blueprint for a protein called TATA box-binding protein (TBP), the protein is formed in cells in a defective form. This also affects its function. "One consequence of this is that the protein forms detectable protein deposits in the brain and damages the nerve cells via molecular mechanisms that have not yet been fully elucidated," explains Jonasz Weber.
As a consequence, those affected by the disease develop symptoms such as movement disorders, seizures, impairment of mental performance as well as changes in nature and behavior, which are associated with the breakdown of tissues such as the cerebellum and brain stem.









